Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials

Here, we report real-world evidence on the safety and efficacy of nilotinib as a first-line treatment in elderly patients with chronic phase CML, treated in 18 Italian centers. Sixty patients aged > 65 years (median age 72 years (65–84)) were reported: 13 patients were older than 75 years. Comorb...

Descripción completa

Detalles Bibliográficos
Autores principales: Luciano, Luigia, Latagliata, Roberto, Gugliotta, Gabriele, Annunziata, Mario, Tiribelli, Mario, Martino, Bruno, Sica, Antonello, Esposito, Maria Rosaria, Bocchia, Monica, Galimberti, Sara, Sorà, Federica, Albano, Francesco, Palmieri, Raffaele, Pregno, Patrizia, Dragani, Matteo, Iovine, Maria, Sica, Simona, Iurlo, Alessandra, Castagnetti, Fausto, Rosti, Gianantonio, Breccia, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182159/
https://www.ncbi.nlm.nih.gov/pubmed/37079069
http://dx.doi.org/10.1007/s00277-023-05159-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182159/
https://www.ncbi.nlm.nih.gov/pubmed/37079069
http://dx.doi.org/10.1007/s00277-023-05159-9

Ejemplares similares